Rubicon Research earnings beat supports margin guidance and US manufacturing growth

Investment View and 1QFY27 Earnings Beat

Motilal Oswal Financial Services reiterated its Buy recommendation on Rubicon Research after what it describes as the company’s fourth consecutive post-IPO earnings beat. The broker attributes the consistent outperformance to superior execution against management’s promises.

Margins and Operating Leverage

Gross margin declined 240 basis points year-on-year to 68.4% because outsourced manufacturing represented a higher share of sales. However, gross margin improved sequentially as Rubicon Research exited lower-margin business and increased in-house manufacturing.

EBITDA margin expanded 180 basis points year-on-year to a multi-quarter high of 24.2%, ahead of Motilal Oswal’s 22.3% forecast. Operating leverage supported the performance, with employee expenses and other expenses declining by 50 basis points and 360 basis points, respectively, as proportions of sales.

R&D expense increased 80 basis points year-on-year to 10.9% of sales, or Rs 58 crore, and is fully charged to the profit and loss account.

Management Guidance and Investment Programme

Management raised its FY27 EBITDA-margin guidance to about 23% from the earlier 22–23% range, despite ESOP costs, commercial investments and pre-revenue costs at the New Jersey and Pithampur facilities.

Management reiterated its plan to invest Rs 500 crore in R&D across FY26, FY27 and 1QFY28. Rubicon Research had spent Rs 250 crore in the first five quarters and remained on track to complete the programme by 1QFY28. The Arinna acquisition, completed in April 2026, contributed about Rs 12 crore of 1QFY27 revenue without a material EBITDA contribution.

Operating Indicators and Product Progress

US dollar revenue increased 32% year-on-year to USD 55 million, despite sequential moderation caused by tactical portfolio optimisation aimed at improving profitability. Pricing was stable, while product concentration continued to decline. Specialty products accounted for 36% of gross profit in 1QFY27.

Rubicon Research received two ANDA approvals, taking active approved products to 86 and commercialised products to 76, representing an 88% commercialisation rate. The broker highlights R&D productivity of 6.1 times for FY27E and continued market-share gains in mature products. Products launched in FY19 remained ranked number one at FY26-end.

Regulatory Execution and Manufacturing Expansion

Pithampur, acquired in June 2025, received USFDA regulatory filing approval just over a month after its June 2026 inspection, which had two procedural observations. The facility is targeted for commercialisation from 1QCY27.

Rubicon Research also acquired a USFDA-compliant New Jersey manufacturing facility for an enterprise value of USD 2.9 million. Management expects the US site to enable government business, closer customer access and specialty high-value products. Commercial operations are targeted in CY27 after quality-system implementation.

Management noted that capacity additions can lag sales growth, requiring initial outsourcing before manufacturing is brought in-house.

Financial Outlook and Earnings Estimates

Motilal Oswal raised its FY27 and FY28 earnings estimates by 7.6% and 5%, respectively, reflecting higher in-house manufacturing, market-share gains and new-launch momentum.

Valuation and Key Execution Considerations

The Rs 1,915 target price is based on a 70 times price-to-earnings multiple. The valuation is supported by expected sustained growth, high returns despite around 25% of capital employed not yet generating meaningful revenue, disciplined capital allocation and governance.

Key execution considerations include the gross-margin effect of outsourcing, the ramp-up of the Pithampur and New Jersey facilities, and delivery of the planned R&D and commercial investments.